The generic version of Erleada is set to be available after 30 April 2038, when the last patent expires. However, drug patent challenges can be filed against Erleada from 14 February 2022.
Erleada is used in the treatment of various stages of prostate cancer, including metastatic castration-sensitive prostate cancer (mcspc) and non-metastatic, castration-resistant prostate cancer (nm-crpc). It can be used in combination with a gnrh agonist or androgen deprivation therapy to improve metastasis free survival.
Erleada has a total of 10 patents, none of which have expired. The patents protect various aspects of the drug, such as its specific use in treating different stages of prostate cancer and the specific chemical structure of Apalutamide. The last patent, related to the treatment of non-metastatic, castration-resistant prostate cancer, will expire on 30 April 2038. Below are the details of the patents: